AbbVie Inc  ABBV  (XNYS)

**Morningstar Rating**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Morningstar Pillars**

<table>
<thead>
<tr>
<th>Economic Moat</th>
<th>Analyst</th>
<th>Quantitative</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Valuation</strong></td>
<td>Narrow</td>
<td>Wide</td>
</tr>
<tr>
<td><strong>Uncertainty</strong></td>
<td>Medium</td>
<td>High</td>
</tr>
<tr>
<td><strong>Financial Health</strong></td>
<td>—</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

Source: Morningstar Equity Research

**Quantitative Valuation**

<table>
<thead>
<tr>
<th>Morningstar Rating</th>
<th>Last Price</th>
<th>Fair Value Estimate</th>
<th>Price/Fair Value</th>
<th>Trailing Dividend Yield %</th>
<th>Forward Dividend Yield %</th>
<th>Market Cap (Bil)</th>
<th>Industry</th>
<th>Stewardship</th>
</tr>
</thead>
<tbody>
<tr>
<td>★★★★</td>
<td>78.67 USD</td>
<td>102.00 USD</td>
<td>0.77</td>
<td>5.16</td>
<td>5.44</td>
<td>116.29</td>
<td>Drug Manufacturers</td>
<td>Major</td>
</tr>
</tbody>
</table>

24 Apr 2019 21:45, UTC  
24 Apr 2019 01 Dec 2018 00:04, UTC

Important Disclosure:

The conduct of Morningstar's analysts is governed by Code of Ethics/Code of Conduct Policy, Personal Security Trading Policy (or an equivalent), and Investment Research Policy. For information regarding conflicts of interest, please visit http://global.morningstar.com/equitydisclosures

AbbVie Posts Solid 1Q, With Cancer Drugs and U.S. Humira Sales

**Offsetting Biosimilar Pressure**

**Business Strategy and Outlook**

Damien Conover, CFA, Sector Director, 21 April 2018

While AbbVie holds a strong portfolio of marketed and pipeline drugs, the increasing competition to the company's key drug Humira should slow the growth for the company. At over 50% of total sales and a higher portion of earnings (due to higher margin revenue), Humira is a key determinant of AbbVie’s performance over the next three years.

With approvals in rheumatoid arthritis, psoriasis, and Crohn's disease, Humira should continue to grow in 2018 as these markets as penetration rates are below 25% on average, but longer-term challenges are emerging. Despite a favorable near-term outlook for Humira in 2018, uncertainty around encroaching competition will likely weigh on investor sentiment toward the company. In particular, new JAK inhibitors, IL-17 and IL-23 antibodies represent major drug advancements in rheumatoid arthritis and psoriasis, which will likely lead to some market share losses for Humira. Also, while Humira’s biologic composition and longer-lasting patents may deter generic completion following the late-2016 key patent loss in the U.S. and the 2018 patent loss in Europe, we model close to 20% annual revenue declines for Humira by 2021.

Partly offsetting Humira's eventual declines, AbbVie looks well-positioned with the next generation immunology drugs. In particular, pipeline drugs have shown improved efficacy and safety over Humira and other currently leading treatment options.

Beyond immunology, cancer drug Imbruvica is the next-biggest sales contributor. Imbruvica’s strong clinical data in several forms of blood cancer should lead to peak sales above $6 billion. AbbVie’s remaining drugs are largely mature with patent expirations long past, but have manufacturing or specific dosing complexities which make generic competition less likely.

Looking forward, AbbVie’s pipeline is weighted heavily toward new cancer drugs. In particular, AbbVie’s pipeline should lead to an increasingly strong position in blood cancer. The company should be able to leverage its solid entrenchment with Imbruvica to launch the new drugs.

**Analyst Note**

Damien Conover, CFA, Sector Director, 25 April 2019

AbbVie reported first-quarter results slightly ahead of our expectations, but we don’t expect any significant impact to our fair value estimate based on the minor outperformance, and we continue to view the stock as undervalued. With its increasing focus on the erosion of sales from immunology drug Humira, we believe the investment community is not fully appreciating the company’s solid pipeline of next-generation immunology drugs. While we expect the Humira biosimilar pressure to increase internationally and to start in 2023 in the U.S., we believe the company has a strong enough position with several other marketed drugs and new pipeline drugs to support a narrow moat.

In the quarter, total sales were largely flat operationally, with international declines from Humira offset by growth in oncology drugs and U.S. Humira sales, a trend we expect to continue throughout the year. However, as AbbVie laps the heavy international biosimilar Humira competition later in the year, we expect growth will improve in 2020. Also, AbbVie is making solid strides in bringing next-generation immunology drugs to the market that hold superior profiles over Humira. The recent approval of Skryzi brings a new psoriasis drug to the market with leading efficacy and a slight dosing advantage over Johnson & Johnson’s Tremfya, which holds a similar mechanism of action. Also, we expect approval of rheumatoid arthritis drug upadacitinib in the third quarter, and the drug looks well positioned for refractory patients.

Beyond the new launches, AbbVie’s currently marketed cancer drugs Imbruvica and Venclexta continue to post strong growth, and we expect this to continue as both drugs move into earlier lines of therapy. While AbbVie looks increasingly well positioned for the biosimilar Humira competition in the U.S. expected in 2023, we do expect significant total sales declines in 2023-24 (down 9% and 16%, respectively) before stabilizing in 2025.

**Bulls Say**

- AbbVie supports a strong dividend yield, which should act as valuation support, as the cash flows to support the dividend look secure over the next few years.
- AbbVie’s increasing entrenchment in blood cancers should bode well for growth as pricing power remains solid in this therapeutic area of the pharmaceutical market.
- AbbVie’s next generation immunology drugs targeting the I23 and JAK pathways should help mitigate the competitive threats facing Humira.

**Bears Say**

- Several of AbbVie’s pipeline drugs in immunology have mechanisms of action similar to drugs already approved, taking away the first mover advantage for AbbVie.
- The high profit margins on Humira will likely cause an amplified impact on earnings as sales are lost to eventual biosimilar competition.
- The pricing power of hepatitis C drugs has eroded significantly over the past few years, which may put further pressure on AbbVie next generation hepatitis C platform.

© Morningstar 2019. All Rights Reserved. Unless otherwise provided in a separate agreement, you may use this report only in the country in which its original distributor is based. The information, data, analyses and opinions presented herein do not constitute investment advice, are provided solely for informational purposes and therefore are not an offer to buy or sell a security, and are not intended to be the basis for any investment decision. The opinions expressed are as of the date written and are subject to change without notice. Except as otherwise required by law, Morningstar shall not be responsible for any trading decisions, damages or other losses resulting from, or related to, the information, data, analyses or opinions or their use. The information contained herein is the property of Morningstar and may not be reproduced, in whole or in part, or used in any manner, without the prior written consent of Morningstar. Investment research is produced and issued by subsidiaries of Morningstar, Inc., including, but not limited to, Morningstar Research Services LLC, registered with and governed by the U.S. Securities and Exchange Commission. To order reprints, call +1 312-986-0675. To license the research, call +1 312-466-8689. Please see important disclosures at the end of this report.
AbbVie Inc  ABBV  (XNYS)

<table>
<thead>
<tr>
<th>Morningstar Rating</th>
<th>Last Price</th>
<th>Fair Value Estimate</th>
<th>Price/Fair Value</th>
<th>Trailing Dividend Yield %</th>
<th>Forward Dividend Yield %</th>
<th>Market Cap (Bil)</th>
<th>Industry</th>
<th>Stewardship</th>
</tr>
</thead>
<tbody>
<tr>
<td>★★★★</td>
<td>78.67 USD</td>
<td>102.00 USD</td>
<td>0.77</td>
<td>5.16</td>
<td>5.44</td>
<td>116.29</td>
<td>Drug Manufacturers</td>
<td>Standard</td>
</tr>
</tbody>
</table>

Close Competitors

- Johnson & Johnson JNJ
  - Currency: USD
  - Market Cap: 370,658
  - TTM Sales: 81,581
  - Operating Margin: 24.58
  - TTM/PE: 25.77
- Pfizer Inc PFE
  - Currency: USD
  - Market Cap: 218,575
  - TTM Sales: 53,847
  - Operating Margin: 28.04
  - TTM/PE: 21.19
- Merck & Co Inc MRK
  - Currency: USD
  - Market Cap: 193,033
  - TTM Sales: 42,294
  - Operating Margin: 21.12
  - TTM/PE: 32.26
- Eli Lilly and Co LLY
  - Currency: USD
  - Market Cap: 114,509
  - TTM Sales: 24,556
  - Operating Margin: 28.18
  - TTM/PE: 37.74

Damien Conover, Sector Director, 15 January 2019

We believe AbbVie supports a narrow moat based on patented-protected drugs, intellectual intangibles, and a powerful salesforce. As is the case for most drug firms, the core of AbbVie’s moat lies in its portfolio of patent-protected drugs. However, unlike AbbVie’s Big Pharma peers, which tend to carry wide moats, one drug (Humira) represents the majority of AbbVie’s sales (more than 50%) and profits (greater than 70%). As a result of both emerging branded competition to Humira in the immediate term and a potential generic biosimilar threat in the 2018-20 time frame, we believe excess returns are likely to persist for 10 years, but we cannot be as certain of this for our 20-year outlook, which would be needed for a wide-moat rating. While we do model in Humira sales declines beginning in 2020, the rate of decline will likely be more gradual than a typical small molecule-branded drug facing generic competition, because of the complexities in developing and marketing a biosimilar (generic biologic).

Nevertheless, AbbVie derives enormous cash flows from its current product portfolio to fund ongoing discovery and development of the next generation of drugs. The large cash flows create an economy of scale that enables AbbVie to fund the average $800 million required for a new drug. While not as strong as other Big Pharma firms, AbbVie’s R&D has created a database of intellectual insights that should help increase the odds of successful drug development. Finally, AbbVie’s entrenched salesforce in one of the most sought-after therapeutic areas of immunology should help the firm launch its next generation of drugs and make the company a leading candidate for smaller drug firms needing help to develop and commercialize innovative new drugs.

Risk & Uncertainty

Damien Conover, Sector Director, 15 January 2019

Similar to other drug firms, AbbVie faces the risks of new drug failures, reimbursement challenges for new drugs, and drug pricing cuts by large payer groups that are growing increasingly price-sensitive. Further, AbbVie’s high concentration of Humira sales makes the company significantly exposed to any new competitive threats to Humira, both from biosimilars and new branded drug competition.

Stewardship

Damien Conover, Sector Director, 15 January 2019

We believe AbbVie’s management team has demonstrated Standard stewardship. While the failed acquisition attempt for Shire is concerning, we believe the new abrupt U.S. Treasury laws largely caused the acquisition to collapse, somewhat giving management a pass. Nevertheless, the $1.6 billion breakup fee related to the failed Shire deal does show that management didn’t gauge the political landscape correctly. Further, the $21 billion Pharmacia acquisition appears to be a fair use of capital if Imbruvica can reach our $6 billion plus peak sales projection.

Turning to management specifically, AbbVie is led by Rick Gonzalez, who joined Abbott in 1977 and held many managerial posts throughout his career at the firm. However, he only recently led the drug group starting in July 2010 after a brief retirement. His relatively short tenure in the key field of drug commercialization and
development is a concern, but execution has been going well under his leadership. Backing up Gonzalez, CFO Bill Chase has been with Abbott for more than 20 years. Chase’s background in licensing and acquisitions is helpful, as AbbVie will need to redeploy the strong cash flows from Humira into acquisitions and partnering to augment the company’s developing pipeline. However, Chase’s recent announcement to retire in mid-2019 will leave a void that we expect will be replaced by an internal candidate.
**AbbVie Inc**  
ABBV (XNYS)  

<table>
<thead>
<tr>
<th>Morningstar Rating</th>
<th>Last Price</th>
<th>Fair Value Estimate</th>
<th>Price/Fair Value</th>
<th>Trailing Dividend Yield %</th>
<th>Forward Dividend Yield %</th>
<th>Market Cap (Bil)</th>
<th>Industry</th>
<th>Stewardship</th>
</tr>
</thead>
<tbody>
<tr>
<td>★★★★</td>
<td>78.67 USD</td>
<td>102.00 USD</td>
<td>0.77</td>
<td>5.16</td>
<td>5.44</td>
<td>116.29</td>
<td>Drug Manufacturers - Major</td>
<td>Standard</td>
</tr>
<tr>
<td>21:45, UTC</td>
<td></td>
<td>00.04, UTC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Analyst Notes Archive**

**AbbVie Posts Solid 30, but European Humira Biosimilar Price Discounts Weigh on Growth Outlook**  
Damien Conover, Sector Director, 02 November 2018  

AbbVie reported solid third-quarter results, with lower expenses leading to better-than-expected bottom-line growth, but we don’t expect any major changes to our fair value estimate based on the minor outperformance. We view the stock as undervalued, with the market likely overly concerned about the Humira biosimilar competition and not appreciating the pipeline. Even though immunology drug Humira (62% of total sales) continues to post steady gains, up 10%, we expect biosimilar pressures to begin to cause this key pillar to decline in 2019. The high concentration of profits from Humira and the likely future declines lead us to view the company’s moat as narrow even though the firm has a strong developing pipeline and steady portfolio of currently marketed drugs.

Beyond the Humira gains, hepatitis C drug Mavyret and hematology drugs were key growth drivers that led to total growth of 19%, but we expect this total growth rate to slow significantly in 2019. European biosimilar pressure to Humira started in October and management’s expectation of international discounting (including countries without biosimilars) of 26-27% is higher than we expected, likely due to the high number of simultaneous biosimilar launches. Also, we expect biosimilar pressure in the U.S. in late 2020, ahead of the 2023 time frame announced in settlements for some biosimilars, as we view an at-risk launch by Pfizer as likely by 2020. In addition to the pressure from Humira, we expect the bolus demand for Mavyret to level off in 2019, resulting in very minor growth for the drug next year.

Offsetting the expected slowing growth from Humira and Mavyret in 2019, we believe the hematology drugs Imbruvica and Venclexta will continue to post strong gains and the new pipeline launches should help stabilize the business. We expect the recent launch of endometriosis drug Orilissa, and the likely 2019 launches of immunology drugs risankizumab and upadacitinib to add three new major blockbusters.

AbbVie and Pfizer settle on Humira Patents, Reducing the Likelihood of an At-Risk Launch  
Damien Conover, Sector Director, 30 November 2018  

We are increasing our AbbVie fair value estimate to $102, following the Humira licensing agreement between AbbVie and Pfizer, allowing Pfizer access to the U.S. market for its biosimilar version of Humira in November 2023. Before this announcement, we had expected Pfizer to launch its biosimilar Humira at-risk at some time close to 2020. However, following this announcement, an at-risk launch looks more unlikely by Pfizer. The strong patent protection AbbVie has developed around Humira has proven more difficult to penetrate than we had initially expected. Typically, noncomposition-of-matter patents don’t hold off generic competition. However, in this case, the complexity of Humira’s biologic structure and the large amount of additional noncomposition-of-matter patents makes the case against at-risk launch stronger. The additional years of exclusivity drive our fair value estimate to $102 from $97 and provide AbbVie a few more years of strong cash flows, which we expect will be used to help fund research and development of next-generation drugs, supporting the firm’s narrow moat. However, we do expect a significant decline in Humira sales following the buildup of biosimilar competition in the U.S. starting in 2023 with a 30% decline projected, followed by a 50% decline in 2024 as several biosimilar versions of Humira will likely drive down the price of the drug.

AbbVie Posts Steady 4Q and Offers Slightly Disappointing 2019 Outlook, but Shares Look Undervalued  
Damien Conover, Sector Director, 25 January 2019  

Along with fourth-quarter results that largely met our expectations and slightly underperformed consensus expectations, AbbVie provided 2019 guidance slightly below our projections. We don’t expect any meaningful change in our fair value estimate, however. AbbVie’s 2019 guidance for oncology drug Venclexta and endometriosis drug Orilissa is slightly behind our projections, but we continue to expect both drugs will develop into major sales contributors with 2022 sales estimates of $3 billion and $300 million, respectively. Also, increased generic competition to testosterone therapy AndroGel will weigh on 2019. However, our sales decline of 30% expected for Humira internationally due to biosimilars is in line with management’s guidance. Despite these headwinds in 2019, AbbVie is reasonably well positioned with new drugs to mitigate most of the generic pressures affecting Humira over the long term, supporting our narrow moat.
rating. However, we lack conviction to award a wide moat rating, given the higher level of uncertainty in offsetting generic Humira pressures, as the drug represents close to 60% of total sales.

In the quarter, international Humira sales fell 15% year over year, and we expect this decline to accelerate in 2019 to 20%. We expect Humira to face further price and volume erosion in 2020 of close to 20%. By 2021, we expect biosimilars to launch in the remaining 25% of international countries, which should lead to our projected decline of 30%. We expect the largest generic headwind in 2023, when biosimilars are likely to enter the United States.

AbbVie is launching several new drugs that should help mitigate Humira biosimilar pressures. We expect major blockbuster potential for immunology drugs risankizumab and upadacitinib, both of which should launch in 2019. Further, currently launched hematology drugs Imbruvica and Venclexta should grow significantly based on new indications and excellent efficacy.

AbbVie Posts Solid 1Q, With Cancer Drugs and U.S. Humira Sales Offsetting Biosimilar Pressure

Damien Conover, Sector Director, 25 April 2019

AbbVie reported first-quarter results slightly ahead of our expectations, but we don’t expect any significant impact to our fair value estimate based on the minor outperformance, and we continue to view the stock as undervalued. With its increasing focus on the erosion of sales from immunology drug Humira, we believe the investment community is not fully appreciating the company’s solid pipeline of next-generation immunology drugs. While we expect the Humira biosimilar pressure to increase internationally and to start in 2023 in the U.S., we believe the company has a strong enough position with several other marketed drugs and new pipeline drugs to support a narrow moat.

In the quarter, total sales were largely flat operationally, with international declines from Humira offset by growth in oncology drugs and U.S. Humira sales, a trend we expect to continue throughout the year. However, as AbbVie lags the heavy international biosimilar Humira competition later in the year, we expect growth will improve in 2020. Also, AbbVie is making solid strides in bringing next-generation immunology drugs to the market that hold superior profiles over Humira. The recent approval of Skyrizi brings a new psoriasis drug to the market with leading efficacy and a slight dosing advantage over Johnson & Johnson’s Tremfya, which holds a similar mechanism of action. Also, we expect approval of rheumatoid arthritis drug upadacitinib in the third quarter, and the drug looks well positioned for refractory patients. Beyond the new launches, AbbVie’s currently marketed cancer drugs Imbruvica and Venclexta continue to post strong growth, and we expect this to continue as both drugs move into earlier lines of therapy. While AbbVie looks increasingly well positioned for the biosimilar Humira competition in the U.S. expected in 2023, we do expect significant total sales declines in 2023-24 (down 9% and 16%, respectively) before stabilizing in 2025.
AbbVie Inc ABBV

Company Profile
AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the company's current profits. The company was spun off from Abbott in early 2013.

Quantitative Scores

<table>
<thead>
<tr>
<th>Score Category</th>
<th>All</th>
<th>Rel Sector</th>
<th>Rel Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quantitative Moat</td>
<td>Wide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valuation</td>
<td>Undervalued</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quantitative Uncertainty</td>
<td>High</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Financial Health</td>
<td>Moderate</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Morningstar Equity Research

Valuation

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue (Mil)</th>
<th>Net Income (Mil)</th>
<th>Operating Margin %</th>
<th>ROE</th>
<th>Market Cap ($Bil)</th>
<th>PE</th>
<th>PEG</th>
<th>Price/Book</th>
<th>Price/Cash Flow</th>
<th>Price/Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>19,960</td>
<td>2,530</td>
<td>5.3</td>
<td>27</td>
<td>75.77</td>
<td>20</td>
<td>1.7</td>
<td>6.2</td>
<td>1.13</td>
<td>3.72</td>
</tr>
<tr>
<td>2015</td>
<td>22,859</td>
<td>3,356</td>
<td>5.3</td>
<td>27</td>
<td>90.66</td>
<td>20</td>
<td>1.7</td>
<td>6.2</td>
<td>1.13</td>
<td>3.72</td>
</tr>
<tr>
<td>2016</td>
<td>25,639</td>
<td>4,536</td>
<td>5.2</td>
<td>27</td>
<td>116.3</td>
<td>20</td>
<td>1.7</td>
<td>6.2</td>
<td>1.13</td>
<td>3.72</td>
</tr>
<tr>
<td>2017</td>
<td>28,216</td>
<td>5,958</td>
<td>5.2</td>
<td>27</td>
<td>131.3</td>
<td>20</td>
<td>1.7</td>
<td>6.2</td>
<td>1.13</td>
<td>3.72</td>
</tr>
<tr>
<td>2018</td>
<td>32,753</td>
<td>8,278</td>
<td>5.2</td>
<td>27</td>
<td>145.2</td>
<td>20</td>
<td>1.7</td>
<td>6.2</td>
<td>1.13</td>
<td>3.72</td>
</tr>
</tbody>
</table>

Source: Morningstar Equity Research

Profitability

<table>
<thead>
<tr>
<th>Year</th>
<th>Return on Equity %</th>
<th>Revenue/Employee (Mil)</th>
<th>Total Return</th>
<th>Capital Spending</th>
<th>Operating Income</th>
<th>Net Income (Mil)</th>
<th>ROA</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>56.9</td>
<td>1.1</td>
<td>211.7</td>
<td>10.9</td>
<td>18.1</td>
<td>2.5</td>
<td>2.3</td>
</tr>
<tr>
<td>2015</td>
<td>56.8</td>
<td>1.1</td>
<td>211.7</td>
<td>10.9</td>
<td>18.1</td>
<td>2.5</td>
<td>2.3</td>
</tr>
<tr>
<td>2016</td>
<td>56.7</td>
<td>1.1</td>
<td>211.7</td>
<td>10.9</td>
<td>18.1</td>
<td>2.5</td>
<td>2.3</td>
</tr>
<tr>
<td>2017</td>
<td>56.6</td>
<td>1.1</td>
<td>211.7</td>
<td>10.9</td>
<td>18.1</td>
<td>2.5</td>
<td>2.3</td>
</tr>
<tr>
<td>2018</td>
<td>56.5</td>
<td>1.1</td>
<td>211.7</td>
<td>10.9</td>
<td>18.1</td>
<td>2.5</td>
<td>2.3</td>
</tr>
</tbody>
</table>

Source: Morningstar Equity Research

Growth Per Share

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue %</th>
<th>Operating Income %</th>
<th>Earnings %</th>
<th>Dividends %</th>
<th>Book Value %</th>
<th>Stock Total Return %</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>16.1</td>
<td>-33.1</td>
<td>10.9</td>
<td>40.2</td>
<td>—</td>
<td>-9.4</td>
</tr>
<tr>
<td>2015</td>
<td>16.2</td>
<td>-33.1</td>
<td>10.9</td>
<td>40.2</td>
<td>—</td>
<td>-9.4</td>
</tr>
<tr>
<td>2016</td>
<td>16.3</td>
<td>-33.1</td>
<td>10.9</td>
<td>40.2</td>
<td>—</td>
<td>-9.4</td>
</tr>
<tr>
<td>2017</td>
<td>16.4</td>
<td>-33.1</td>
<td>10.9</td>
<td>40.2</td>
<td>—</td>
<td>-9.4</td>
</tr>
<tr>
<td>2018</td>
<td>16.5</td>
<td>-33.1</td>
<td>10.9</td>
<td>40.2</td>
<td>—</td>
<td>-9.4</td>
</tr>
</tbody>
</table>

Source: Morningstar Equity Research

Quarterly Revenue & EPS

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue (Mil)</th>
<th>Earnings Per Share ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>7,934.0</td>
<td>1.74</td>
</tr>
<tr>
<td>2017</td>
<td>6,538.0</td>
<td>1.16</td>
</tr>
<tr>
<td>2016</td>
<td>5,958.0</td>
<td>0.83</td>
</tr>
<tr>
<td>2015</td>
<td>5,040.0</td>
<td>0.63</td>
</tr>
</tbody>
</table>

Source: Morningstar Equity Research

Revenue Growth Year on Year %

<table>
<thead>
<tr>
<th>Year</th>
<th>Total Revenue %</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>4.5</td>
</tr>
<tr>
<td>2017</td>
<td>13.9</td>
</tr>
<tr>
<td>2018</td>
<td>21.4</td>
</tr>
</tbody>
</table>

Source: Morningstar Equity Research

© Morningstar 2019. All Rights Reserved. Unless otherwise provided in a separate agreement, you may use this report only in the country in which its original distributor is based. The information, data, analyses and opinions presented herein do not constitute investment advice; are provided solely for informational purposes and therefore is not an offer to buy or sell a security; are not warranted to be correct, complete or accurate; and are subject to change without notice. Except as otherwise required by law, Morningstar shall not be responsible for any trading decisions, damages or other losses resulting from, or related to, the information, data, analyses or opinions or their use. The information herein may not be reproduced, in any manner without the prior written consent of Morningstar. Please use important disclosures at the end of this report.
Qualitative Equity Research Overview

At the heart of our valuation system is a detailed projection of a company’s future cash flows, resulting from our analysts’ research. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into our globally standardized, proprietary discounted cash flow, or DCF, modeling templates. We use scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools to augment this process. We believe this bottom-up, long-term, fundamentally based approach allows our analysts to focus on long-term business drivers, which have the greatest valuation impact, rather than short-term market noise.

Morningstar’s equity research group (“we,” “our”) believes that a company’s intrinsic worth results from the future cash flows it can generate. The Morningstar Rating for stocks identifies stocks trading at an uncertainty-adjusted discount or premium to their intrinsic worth—or fair value estimate, in Morningstar terminology. Five-star stocks sell for the biggest risk-adjusted discount to their fair values whereas 1-star stocks trade at premiums to their intrinsic worth.

Four key components drive the Morningstar rating: (1) our assessment of the firm’s economic moat, (2) our estimate of the stock’s fair value, (3) our uncertainty around that fair value estimate and (4) the current market price. This process ultimately culminates in our single-point star rating.

1. Economic Moat

The concept of an economic moat plays a vital role not only in our qualitative assessment of a firm’s long-term investment potential, but also in the actual calculation of our fair value estimates. An economic moat is a structural feature that allows a firm to sustain excess profits over a long period of time. We define excess economic profits as returns on invested capital (or ROIC) over and above our estimate of a firm’s cost of capital, or weighted average cost of capital (or WACC). Without a moat, profits are more susceptible to erosion.

We have identified five sources of economic moats:

- intangible assets, switching costs, network effect, cost advantage, and efficient scale.
- Companies with a narrow moat are those we believe are more likely than not to achieve normalized excess returns for at least the next 10 years. Wide-moat companies are those in which we have very high confidence that excess returns will remain for 10 years, with excess returns more likely than not to remain for at least 20 years. The longer a firm generates economic profits, the higher its intrinsic value. We believe low-quality no-moat companies will see their normalized returns gravitate toward the firm’s cost of capital more quickly than companies with moats.

To assess the direction of the underlying competitive advantages, analysts perform ongoing assessments of the moat trend. A firm’s moat trend is positive in cases where we think its sources of competitive advantage are growing stronger; stable where we don’t anticipate changes to competitive advantages over the next several years; or negative when we see signs of deterioration.

All the moat and moat trend ratings undergo periodic review and any changes must be approved by the Morningstar Economic Moat Committee, comprised of senior members of Morningstar’s equity research department.

2. Estimated Fair Value

Combining our analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Returns of firms with a wide economic moat rating are assumed to fade to the perpetuity period over a longer period of time than the returns of narrow-moat firms, and both will fade slower than no-moat firms, increasing our estimate of their intrinsic value.

Our model is divided into three distinct stages:

Stage I: Explicit Forecast

In this stage, which can last five to 10 years, analysts make full financial statement forecasts, including items such as revenue, profit margins, tax rates, changes in working-capital accounts, and capital spending. Based on these projections, we calculate earnings before interest, after taxes, or EBIT, and the net new investment, or NNI, to derive our annual free cash flow forecast.

Stage II: Fade

The second stage of our model is the period it will take the company’s return on new invested capital—the return on capital of the next dollar invested (“RONIC”)—to decline (or rise) to its cost of capital. During the Stage II period, we use a formula to approximate cash flows in lieu of explicitly modeling the income statement, balance sheet, and cash flow statement as we do in Stage I. The length of the second stage depends on the strength of the company’s economic moat. We forecast this period to last anywhere from one year (for companies with no economic moat) to 10–15 years or more (for wide-moat companies). During this period, cash flows are forecast using four assumptions: an average growth rate for EBIT over the period, a normalized investment rate, average return on new invested capital, or RONIC, and the number of years until perpetuity, when excess returns cease. The investment rate and return on new invested capital decline until the perpetuity stage is reached. In the case of firms that do not earn their cost of capital, we assume marginal ROICs rise to the firm’s cost of capital (usually attributable to less reinvestment), and we may truncate the second stage.

Stage III: Perpetuity

Once a company’s marginal ROIC hits its cost of capital, we calculate a continuing value, using a standard perpetuity formula. At perpetuity, we assume that any growth or decline in investment in the business neither creates nor destroys value and that any new investment provides a return in line with estimated WACC.

Because a dollar earned today is worth more than a dollar earned tomorrow, we discount our projections of cash flows in stages I, II, and III to arrive at a total present value of expected future cash flows. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the WACC, which is a weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term market-value weights.
Research Methodology for Valuing Companies

3. Uncertainty Around That Fair Value Estimate
Morningstar’s Uncertainty Rating captures a range of likely potential intrinsic values for a company and uses it to assign the margin of safety required before investing, which in turn explicitly drives our stock star rating system. The Uncertainty Rating represents the analysts’ ability to bound the estimated value of the shares in a company around the fair value estimate, based on the characteristics of the business underlying the stock, including operating and financial leverage, sales sensitivity to the overall economy, product concentration, pricing power, and other company-specific factors.

Analysts consider at least two scenarios in addition to their base case: a bull case and a bear case. Assumptions are chosen such that the analyst believes there is a 25% probability that the company will perform better than the bull case, and a 25% probability that the company will perform worse than the bear case. The distance between the bull and bear cases is an important indicator of the uncertainty underlying the fair value estimate.

Our recommended margin of safety widens as our uncertainty of the estimated value of the equity increases. The more uncertain we are about the estimated value of the equity, the greater the discount we require relative to our estimate of the value of the firm before we would recommend the purchase of the shares. In addition, the uncertainty rating provides guidance in portfolio construction based on risk tolerance.

Our uncertainty ratings for our qualitative analysis are low, medium, high, very high, and extreme.

- Low—margin of safety for 5-star rating is a 20% discount and for 1-star rating is 25% premium.
- Medium—margin of safety for 5-star rating is a 30% discount and for 1-star rating is 35% premium.
- High—margin of safety for 5-star rating is a 40% discount and for 1-star rating is 55% premium.
- Very High—margin of safety for 5-star rating is a 50% discount and for 1-star rating is 75% premium.
- Extreme—margin of safety for 5-star rating is a 75% discount and for 1-star rating is 300% premium.

4. Market Price
The market prices used in this analysis and noted in the report come from exchange on which the stock is listed, which we believe is a reliable source.

For more details about our methodology, please go to https://shareholders.morningstar.com.

Morningstar Star Rating for Stocks
Once we determine the fair value estimate of a stock, we compare it with the stock’s current market price on a daily basis, and the star rating is automatically re-calculated at the market close on every day the market on which the stock is listed is open. Please note, there is no predefined distribution of stars. That is, the percentage of stocks that earn 5 stars can fluctuate daily, so the star ratings, in the aggregate, can serve as a gauge of the broader market’s valuation. When there are many 5-star stocks, the stock market as a whole is more undervalued, in our opinion, than when very few companies garner our highest rating.

We expect that if our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years (although it is impossible to predict the exact time frame in which market prices may adjust).

Our star ratings are guideposts to a broad audience and individuals must consider their own specific investment goals, risk tolerance, tax situation, time horizon, income needs, and complete investment portfolio, among other factors.

The Morningstar Star Ratings for stocks are defined below:

- ★★★★★ We believe appreciation beyond a fair risk-adjusted return is highly likely over a multiyear time frame. The current market price represents an excessively pessimistic outlook, limiting downside risk and maximizing upside potential.
- ★★★★ We believe appreciation beyond a fair risk-adjusted return is likely.
- ★★★ Indicates our belief that investors are likely to receive a fair risk-adjusted return (approximately cost of equity).
- ★★★ We believe investors are likely to receive a less than fair risk-adjusted return.
- ★ Indicates a high probability of undesirable risk-adjusted returns from the current market price over a multiyear time frame, based on our analysis. The market is pricing in an excessively optimistic outlook, limiting upside potential and leaving the investor exposed to Capital loss.
Other Definitions

Last Price: Price of the stock as of the close of the market of the last trading day before date of the report.

Stewardship Rating: Represents our assessment of management’s stewardship of shareholder capital, with particular emphasis on capital allocation decisions. Analysts consider companies’ investment strategy and valuation, financial leverage, dividend and share buyback policies, execution, compensation, related party transactions, and accounting practices. Corporate governance practices are only considered if they’ve had a demonstrated impact on shareholder value. Analysts assign one of three ratings: “Exemplary,” “Standard,” and “Poor.” Analysts judge stewardship from an equity holder’s perspective. Ratings are determined on an absolute basis. Most companies will receive a Standard rating, and this is the default rating in the absence of evidence that managers have made exceptionally strong or poor capital allocation decisions.

Quantitative Valuation: Using the below terms, intended to denote the relationship between the security’s Last Price and Morningstar’s quantitative fair value estimate for that security.

- Undervalued: Last Price is below Morningstar’s quantitative fair value estimate.
- Fairly Valued: Last Price is in line with Morningstar’s quantitative fair value estimate.
- Overvalued: Last Price is above Morningstar’s quantitative fair value estimate.

Risk Warning

Please note that investments in securities are subject to market and other risks and there is no assurance or guarantee that the intended investment objectives will be achieved. Past performance of a security may or may not be sustained in future and is no indication of future performance. A security investment return and an investor’s principal value will fluctuate so that, when redeemed, an investor’s shares may be worth more or less than their original cost. A security’s current investment performance may be lower or higher than the investment performance noted within the report. Morningstar’s Uncertainty Rating serves as a useful data point with respect to sensitivity analysis of the assumptions used in our determining a fair value price.

Quantitative Equity Reports Overview

The quantitative report on equities consists of data, statistics and quantitative equity ratings on equity securities. Morningstar, Inc.’s quantitative equity ratings are forward looking and are generated by a statistical model that is based on Morningstar Inc.’s analyst-driven equity ratings and quantitative statistics. Given the nature of the quantitative report and the quantitative ratings, there is no one analyst in which a given report is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative equity ratings used in this report. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.’s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities.

Quantitative Equity Ratings

Morningstar’s quantitative equity ratings consist of:

(i) Quantitative Fair Value Estimate
(ii) Quantitative Star Rating
(iii) Quantitative Uncertainty
(iv) Quantitative Economic Moat
(v) Quantitative Financial Health

(collectively the “Quantitative Ratings”).

The Quantitative Ratings are calculated daily and derived from the analyst-driven ratings of a company’s peers as determined by statistical algorithms. Morningstar, Inc. ("Morningstar," "we," "our") calculates Quantitative Ratings for companies whether it already provides analyst ratings and qualitative coverage. In some cases, the Quantitative Ratings may differ from the analyst ratings because a company’s analyst-driven ratings can significantly differ from other companies in its peer group.

Quantitative Fair Value Estimate: Intended to represent Morningstar’s estimate of the per share dollar amount that a company’s equity is worth today. Morningstar calculates the quantitative fair value estimate using a statistical model derived from the fair value estimate Morningstar’s equity analysts assign to companies. Please go to https://shareholders.morningstar.com for information about fair value estimates Morningstar’s equity analysts assign to companies.

Quantitative Economic Moat: Intended to describe the strength of a firm’s competitive position. It is calculated using an algorithm designed to predict the Economic Moat rating a Morningstar analyst would assign to the stock. The rating is expressed as Narrow, Wide, or None.

- Narrow: assigned when the probability of a stock receiving a “Wide Moat” rating by an analyst is greater than 70% but less than 99%.
- Wide: assigned when the probability of a stock receiving a “Wide Moat” rating by an analyst is greater than 99%.
- None: assigned when the probability of an analyst receiving a “Wide Moat” rating by an analyst is less than 70%.

Quantitative Star Rating: Intended to be the summary rating based on the combination of our Quantitative Fair Value Estimate, current market price, and the Quantitative Uncertainty Rating. The rating is expressed as 1-Star, 2-Star, 3-Star, 4-Star, and 5-Star.

- ★: the stock is overvalued with a reasonable margin of safety.
- ★★: the stock is somewhat overvalued.
- ★★★: the stock is fairly valued.
- ★★★★: the stock is undervalued with a reasonable margin of safety.

Quantitative Uncertainty: Intended to represent Morningstar’s level of uncertainty about the accuracy of the quantitative fair value estimate. Generally, the lower the quantitative Uncertainty, the narrower the potential range of outcomes for that particular company. The rating is expressed as Low, Medium, High, Very High, and Extreme.

- Low: the interquartile range for possible fair values is less than 10%.
- Medium: the interquartile range for possible fair values is less than 15% but greater than 10%.
- High: the interquartile range for possible fair values is less than 35% but greater than 15%.
- Very High: the interquartile range for possible fair values is less than 80% but greater than 35%.
- Extreme: the interquartile range for possible fair values is greater than 80%.

Quantitative Financial Health: Intended to reflect the probability that a firm will face financial distress in the near future. The calculation uses a predictive model designed to anticipate when a company may default on its financial obligations. The rating is expressed as Weak, Moderate, and Strong.

- Weak: assigned when Quantitative Financial Health <0.2
- Moderate: assigned when Quantitative Financial Health is between 0.2 and 0.7
- Strong: assigned when Quantitative Financial Health >0.7
Research Methodology for Valuing Companies

Other Definitions

Last Close: Price of the stock as of the close of the market of the last trading day before date of the report.

Quantitative Valuation: Using the below terms, intended to denote the relationship between the security's Last Price and Morningstar's quantitative fair value estimate for that security.

- Undervalued: Last Price is below Morningstar's quantitative fair value estimate.
- Fairly Valued: Last Price is in line with Morningstar's quantitative fair value estimate.
- Overvalued: Last Price is above Morningstar's quantitative fair value estimate.

This Report has not been made available to the issuer of the security prior to publication.

Risk Warning
Please note that investments in securities are subject to market and other risks and there is no assurance or guarantee that the intended investment objectives will be achieved. Past performance of a security may or may not be sustained in future and is no indication of future performance. A security investment return and an investor's principal value will fluctuate so that, when redeemed, an investor's shares may be worth more or less than their original cost. A security's current investment performance may be lower or higher than the investment performance noted within the report.

The quantitative equity ratings are not statements of fact. Morningstar does not guarantee the completeness or accuracy of the assumptions or models used in determining the quantitative equity ratings. In addition, there is the risk that the price target will not be met due to such things as unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, and tax rate. For investments in foreign markets there are further risks, generally based on exchange rate changes or changes in political and social conditions.

A change in the fundamental factors underlying the quantitative equity ratings can mean that the valuation is subsequently no longer accurate.

For more information about Morningstar's quantitative methodology, please visit http://global.morningstar.com/equitydisclosures.
**General Disclosure**

The analysis within this report is prepared by the person(s) noted in their capacity as an analyst for Morningstar’s equity research group. The equity research group consists of various Morningstar, Inc. subsidiaries (“Equity Research Group”). In the United States, that subsidiary is Morningstar Research Services LLC, which is registered with and governed by the U.S. Securities and Exchange Commission.

The opinions expressed within the report are given in good faith, are as of the date of the report and are subject to change without notice. Neither the analyst nor Equity Research Group commits themselves in advance to whether and in which intervals updates to the report are expected to be made. The written analysis and Morningstar Star Rating for stocks are statements of opinions; they are not statements of fact.

The Equity Research Group believes its analysts make a reasonable effort to carefully research information contained in the analysis. The information on which the analysis is based has been obtained from sources believed to be reliable such as, for example, the company’s financial statements filed with a regulator, company website, Bloomberg and any other the relevant press sources. Only the information obtained from such sources is made available to the issuer who is the subject of the analysis, which is necessary to properly reconcile with the facts. Should this sharing of information result in considerable changes, a statement of that fact will be noted within the report. While the Equity Research Group has obtained data, statistics and information from sources it believes to be reliable, neither the Equity Research Group nor Morningstar, Inc. performs an audit or seeks independent verification of any of the data, statistics, and information it receives.

**General Quantitative Disclosure**

The Quantitative Equity Report (“Report”) is derived from data, statistics and information within Morningstar, Inc.’s database as of the date of the Report and is subject to change without notice. The Report is for informational purposes only, intended for financial professionals and/or sophisticated investors (“Users”) and should not be the sole piece of information used by such Users or their clients in making an investment decision. The quantitative equity ratings noted in the Report are provided in good faith, are as of the date of the Report and are subject to change. While Morningstar has obtained data, statistics and information from sources it believes to be reliable, Morningstar does not perform an audit or seeks independent verification of any of the data, statistics, and information it receives.

The quantitative equity ratings are not a market call, and do not replace the User or User’s clients from conducting their own due-diligence on the security. The quantitative equity rating is not a suitability assessment; such assessments take into account many factors including a person’s investment objective, personal and financial situation, and risk tolerance all of which are factors the quantitative equity rating statistical model does not and did not consider.

Prices noted with the Report are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

**General Disclosure (applicable to both Quantitative and Qualitative Research)**

Unless otherwise provided in a separate agreement, recipients accessing this report may only use it in the country in which the Morningstar distributor is based. Unless stated otherwise, the original distributor of the report is Morningstar Research Services LLC, a U.S.A. domiciled financial institution.

This report is for informational purposes only and has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. This publication is intended to provide information to assist institutional investors in making their own investment decisions, not to provide investment advice to any specific investor. Therefore, investments discussed and recommendations made herein may not be suitable for all investors: recipients must exercise their own independent judgment as to the suitability of such investments and recommendations in the light of their own investment objectives, experience, taxation status and financial position.

The information, data, analyses and opinions presented herein are not warranted to be accurate, correct, complete or timely. Unless otherwise provided in a separate agreement, neither Morningstar, Inc. or the Equity Research Group represents that the report contents meet all of the presentation and/or disclosure standards applicable in the jurisdiction the recipient is located.

Except as otherwise required by law or provided for in a separate agreement, the analyst, Morningstar, Inc. and the Equity Research Group and their officers, directors and employees shall not be responsible or liable for any trading decisions, damages or other losses resulting from, or related to, the information, data, analyses or opinions within the report. The Equity Research Group encourages recipients of this report to read all relevant issue documents (e.g., prospectus) pertaining to the security concerned, including without limitation, information relevant to its investment objectives, risks, and costs before making an
AbbVie Inc  ABBV  (XNYS)

<table>
<thead>
<tr>
<th>Morningstar Rating</th>
<th>Last Price</th>
<th>Fair Value Estimate</th>
<th>Price/Fair Value</th>
<th>Trailing Dividend Yield %</th>
<th>Forward Dividend Yield %</th>
<th>Market Cap (Bil)</th>
<th>Industry</th>
<th>Stewardship</th>
</tr>
</thead>
<tbody>
<tr>
<td>★★★★</td>
<td>78.67 USD</td>
<td>102.00 USD</td>
<td>0.77</td>
<td>5.16</td>
<td>5.44</td>
<td>116.29</td>
<td>Drug Manufacturers - Major</td>
<td>Standard</td>
</tr>
</tbody>
</table>

24 Apr 2019
21:45, UTC

24 Apr 2019
01 Dec 2018
00.04, UTC

investment decision and when deemed necessary, to seek the advice of a legal, tax, and/or accounting professional.

The Report and its contents are not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Morningstar, Inc. or its affiliates to any registration or licensing requirements in such jurisdiction.

Where this report is made available in a language other than English and in the case of inconsistencies between the English and translated versions of the report, the English version will control and supersede any ambiguities associated with any part or section of a report that has been issued in a foreign language. Neither the analyst, Morningstar, Inc., or the Equity Research Group guarantees the accuracy of the translations.

This report may be distributed in certain localities, countries and/or jurisdictions (“Territories”) by independent third parties or independent intermediaries and/or distributors (“Distributors”). Such Distributors are not acting as agents or representatives of the analyst, Morningstar, Inc. or the Equity Research Group. In Territories where a Distributor distributes our report, the Distributor is solely responsible for complying with all applicable regulations, laws, rules, circulars, codes and guidelines established by local and/or regional regulatory bodies, including laws in connection with the distribution third-party research reports.

Conflicts of Interest:

- No interests are held by the analyst with respect to the security subject of this investment research report.
  - Morningstar, Inc. may hold a long position in the security subject of this investment research report that exceeds 0.5% of the total issued share capital of the security. To determine if such is the case, please check http://msi.morningstar.com and http://mdi.morningstar.com.

- Analysts’ compensation is derived from Morningstar, Inc.’s overall earnings and consists of salary, bonuses and in some cases restricted stock.

- Neither Morningstar, Inc. or the Equity Research Group receives commissions for providing research nor do they charge companies to be rated.

- Neither Morningstar, Inc. or the Equity Research Group is a market maker or a liquidity provider of the security noted within this report.

- Neither Morningstar, Inc. or the Equity Research Group has been a lead manager or co-lead manager over the previous 12-months of any publicly disclosed offer of financial instruments of the issuer.

- Morningstar, Inc.’s investment management group does have arrangements with financial institutions to provide portfolio management/investment advice of which an analyst may issue investment research reports on. However, analysts do not have authority over Morningstar’s investment management group’s business arrangements nor allow employees from the investment management group to participate or influence the analysis or opinion prepared by them.

- Morningstar, Inc. is a publically traded company (Ticker Symbol: MORN) and thus a financial institution the security of which is the subject of this report may own more than 5% of Morningstar, Inc.’s total outstanding shares. Please access Morningstar, Inc.’s proxy statement, “Security Ownership of Certain Beneficial Owners and Management” section https://shareholders.morningstar.com/investor-relations/financials/sec-filings/default.aspx

- Morningstar, Inc. may provide the product issuer or its related entities with services or products for a fee and on an arms’ length basis including software products and licenses, research and consulting services, data services, licenses to republish our ratings and research in their promotional material, event sponsorship and website advertising.

Further information on Morningstar, Inc.’s conflict of interest policies is available from http://global.morningstar.com/equitydisclosures. Also, please note analysts are subject to the CFA Institute’s Code of Ethics and Standards of Professional Conduct.

For a list of securities which the Equity Research Group currently covers and provides written analysis on please contact your local Morningstar office. In addition, for historical analysis of securities covered, including their fair value estimate, please contact your local office.

For Recipients in Australia: This Report has been issued and distributed in Australia by Morningstar Australasia Pty Ltd (ABN: 95 090 685 544, ASFL: 240892), Morningstar Australasia Pty Ltd is the provider of the general advice (‘the Service’) and takes responsibility for the production of this report. The Service is provided through the research of investment products. To the extent the Report contains general advice it has been prepared without reference to an investor’s objectives, financial situation or needs. Investors should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement before making any decision to invest. Refer to our Financial Services Guide (FSG) for more information at http://www.morningstar.com.au/fsg.pdf.

For Recipients in Canada: This research is not prepared subject to Canadian disclosure requirements.

For Recipients in Hong Kong: The Report is distributed by Morningstar Investment Management Asia Limited, which is regulated by the Hong Kong Securities and Futures Commission to provide services to professional investors only. Neither Morningstar Investment Management Asia Limited, nor its representatives, are acting or will be deemed to be acting as an investment advisor to any recipients of this information unless expressly agreed to by Morningstar Investment Management Asia Limited. For enquiries regarding this research, please contact a Morningstar Investment Management Asia Limited Licensed Representative at http://global.morningstar.com/equitydisclosures.

For Recipients in India: This Investment Research is issued by Morningstar Investment Adviser India Private Limited. Morningstar Investment Adviser India Private Limited is registered with the Securities and Exchange Board of India (Registration number INA000001357) and provides investment advice and research. Morningstar Investment Adviser India Private Limited has not been the subject of any disciplinary action by

© Morningstar 2019. All Rights Reserved. Unless otherwise provided in a separate agreement, you may use this report only in the country in which its original distributor is based. The information, data, analyses and opinions presented herein do not constitute investment advice, are not guaranteed as to accuracy, completeness or timeliness and do not constitute a recommendation of any investment. The opinions expressed are as of the date written and are subject to change without notice. Except as otherwise required by law, Morningstar shall not be liable for any trading decisions, damages or other losses resulting from, or attributable to, the information, data, analyses or opinions or their use. The information contained herein is the property of Morningstar and may not be reproduced, in whole or in part, in any manner, without the prior written consent of Morningstar. Investment research is produced and issued by subsidiaries of Morningstar, Inc. including, but not limited to, Morningstar Research Services LLC, registered with and governed by the U.S. Securities and Exchange Commission. To order reprints, call: +1 312-696-6100. To license the research, call: +1 312-696-6808.
**AbbVie Inc**  **ABBV** (XNYS)

<table>
<thead>
<tr>
<th>Morningstar Rating</th>
<th>Last Price</th>
<th>Fair Value Estimate</th>
<th>Price/Fair Value</th>
<th>Trailing Dividend Yield %</th>
<th>Forward Dividend Yield %</th>
<th>Market Cap (Bil)</th>
<th>Industry</th>
<th>Stewardship</th>
</tr>
</thead>
<tbody>
<tr>
<td>★★★★</td>
<td>78.67 USD</td>
<td>102.00 USD</td>
<td>0.77</td>
<td>5.16</td>
<td>5.44</td>
<td>116.29</td>
<td>Drug Manufacturers</td>
<td>Standard</td>
</tr>
</tbody>
</table>

24 Apr 2019 21:45, UTC  
24 Apr 2019 00:04, UTC

SEBI or any other legal/regulatory body. Morningstar Investment Adviser India Private Limited is a wholly owned subsidiary of Morningstar Investment Management LLC. In India, Morningstar Investment Adviser India Private Limited has one associate, Morningstar India Private Limited, which provides data related services, financial data analysis and software development.

The Research Analyst has not served as an officer, director or employee of the fund company within the last 12 months, nor has it or its associates engaged in market making activity for the fund company.

*The Conflicts of Interest disclosure above also applies to relatives and associates of Manager Research Analysts in India # The Conflicts of Interest disclosure above also applies to associates of Manager Research Analysts in India. The terms and conditions on which Morningstar Investment Adviser India Private Limited offers Investment Research to clients, varies from client to client, and are detailed in the respective client agreement.

**For recipients in Japan:** The Report is distributed by Ibbotson Associates Japan, Inc., which is regulated by Financial Services Agency. Neither Ibbotson Associates Japan, Inc., nor its representatives, are acting or will be deemed to be acting as an investment advisor to any recipients of this information.

For recipients in Singapore: This Report is distributed by Morningstar Investment Adviser Singapore Pte Limited, which is licensed by the Monetary Authority of Singapore to provide financial advisory services in Singapore. Investors should consult a financial adviser regarding the suitability of any investment product, taking into account their specific investment objectives, financial situation or particular needs, before making any investment decisions.